GlassScriptPhysician profile
Phelps James Peter Lambert
NPI 1083059406
$9,482.30
in general payments reported to CMS, 2019-2025
60 companies · $1,853 in 2025
The $1,853 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $504 · 2021: $1,246 · 2022: $1,770 · 2023: $2,047 · 2024: $754 · 2025: $1,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,654.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,458.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $844.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $802.66 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $630.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $574.97 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $393.11 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $381.07 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $366.70 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Amarin Pharma, INC. | $314.74 | 2019-2023 | |
| Genzyme Corporation | $314.30 | 2025 | |
| Amgen INC. | $296.39 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $253.28 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $248.62 | 2019-2025 | |
| Daiichi Sankyo INC. | $204.92 | 2019-2023 | Injectafer |
| Abbott Laboratories | $188.06 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phelps Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.